TriangleNCT01010126 · OUTCOME
Time to Disease Progression
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from registration to disease progression, assessed up to 3 years
What was measured
Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for evaluation, that patient will be censored for progression of disease at day one post-registration.
Analysis population: All patients that began protocol treatment and were evaluated for response are included in this analysis.
Groups in this outcome
Endometrial Cohort
Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Ovarian Cohort
Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Hepatocellular Cohort
Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Carcinoid Cohort
Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Islet Cell (Double Agent) Cohort
Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Islet Cell (Bevacizumab-only) Cohort
Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Endometrial Cohort | 26 |
| Ovarian Cohort | 58 |
| Hepatocellular Cohort | 27 |
| Carcinoid Cohort | 55 |
| Islet Cell (Double Agent) Cohort | 54 |
| Islet Cell (Bevacizumab-only) Cohort | 24 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Endometrial Cohort | 6.0 | Not reported | 2.5 | 9.8 | Not reported |
| Ovarian Cohort | 5.6 | Not reported | 4.3 | 6.4 | Not reported |
| Hepatocellular Cohort | 8.0 | Not reported | 5.8 | 10.9 | Not reported |
| Carcinoid Cohort | 15.2 | Not reported | 11.4 | 24.2 | Not reported |
| Islet Cell (Double Agent) Cohort | 13.1 | Not reported | 11.2 | 16.6 | Not reported |
| Islet Cell (Bevacizumab-only) Cohort | 18.0 | Not reported | 10.6 | 37.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.5
- upper Limit
- 9.8
- value
- 6.0
- group Id
- OG001
- lower Limit
- 4.3
- upper Limit
- 6.4
- value
- 5.6
- group Id
- OG002
- lower Limit
- 5.8
- upper Limit
- 10.9
- value
- 8.0
- group Id
- OG003
- lower Limit
- 11.4
- upper Limit
- 24.2
- value
- 15.2
- group Id
- OG004
- lower Limit
- 11.2
- upper Limit
- 16.6
- value
- 13.1
- group Id
- OG005
- lower Limit
- 10.6
- upper Limit
- 37.0
- value
- 18.0
- denoms
- counts
- group Id
- OG000
- value
- 26
- group Id
- OG001
- value
- 58
- group Id
- OG002
- value
- 27
- group Id
- OG003
- value
- 55
- group Id
- OG004
- value
- 54
- group Id
- OG005
- value
- 24
- units
- Participants
- description
- Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for evaluation, that patient will be censored for progression of disease at day one post-registration.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Endometrial Cohort
- description
- Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG001
- title
- Ovarian Cohort
- description
- Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG002
- title
- Hepatocellular Cohort
- description
- Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG003
- title
- Carcinoid Cohort
- description
- Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG004
- title
- Islet Cell (Double Agent) Cohort
- description
- Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG005
- title
- Islet Cell (Bevacizumab-only) Cohort
- param Type
- MEDIAN
- population Description
- All patients that began protocol treatment and were evaluated for response are included in this analysis.
- reporting Status
- POSTED
- time Frame
- Time from registration to disease progression, assessed up to 3 years
- title
- Time to Disease Progression
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice